2026 European HealthTech M&A Outlook: Key Emerging Themes and Market Forces, Liquidity Pressures and the Artificial Intelligence Deflationary Wave

Nelson Advisors
3 hours ago
15 min read

The European healthcare technology and medical technology sectors have reached a definitive operational and financial inflection point. Following a period of post-pandemic recalibration, the transaction landscape has transitioned into an era of disciplined industrial maturity, widely characterised by market analysts as the "Great Rationalisation".

The speculative business models of the early 2020s, which prioritised user acquisition and un-monetised top-line expansion, have been retired in favour of the "Industrialisation of Care". This defining theme represents a structural shift toward scalable, profit-generating platforms that leverage operational leverage, vertical integration, and regulatory fortitude to dominate their respective sub-sectors.

While investment capital remains abundant, it has become highly selective. Despite macroeconomic headwind and a contraction of 279 fewer transactions compared to the prior year, Europe successfully logged over 1,100 healthcare deals.

The transactional activity was heavily front-loaded, with Q1 logging 356 transactions, while the subsequent quarters stabilised at an average of 248 deals each. This overall contraction occurred alongside a dramatic 276% year-to-date surge in European healthcare sponsor buyout deals, driven by private equity funds seeking to deploy record levels of dry powder in highly defensive sectors.

The resulting environment is characterised by a stark bifurcation in asset desirability, dictated by "Regulatory Darwinism", a clearing event where the cost of compliance with the EU Medical Device Regulation (MDR), In Vitro Diagnostic Regulation (IVDR), and the newly enforced EU AI Act acts as a binary filter for investor commitment. Concurrently, structural blockages in traditional exit markets have elevated private equity roll-ups and strategic "rent-to-own" corporate partnerships as the primary pathways to liquidity.

Key Emerging Themes and Market Forces

The consolidation wave sweeping through Europe is structurally uneven, driven by a polarisation in asset desirability and distinct transaction rationales.

The Bifurcation of Asset Desirability

The European healthcare transaction landscape is divided into two distinct operating models:

Analogue Healthcare Services: Highly fragmented, clinic-based verticals, including dental, veterinary, ophthalmology and fertility clinics, are witnessing intensified private equity-backed buy-and-build roll-up activity. Sponsors are exploiting attractive entry multiples in Southern and Eastern Europe, where market saturation is low relative to the highly consolidated UK and Nordic markets. This trend is illustrated by high-profile strategic acquisitions, such as French ophthalmological group EssilorLuxottica acquiring the UK-based integrated ophthalmology platform Optegra Eye Health Care, and the leading pan-European diagnostic imaging group Affidea acquiring Alfamed Patomorfologia in Poland.
Digital and High-Technology Segments: Advanced digital health technologies, including artificial intelligence-enabled radiology, digital pathology, and tech-enabled home care, are experiencing strategic consolidation. Hardware incumbents and large-cap technology firms are actively acquiring software innovators to secure data sovereignty and construct robust regulatory moats rather than buying pure revenue growth.

Shift to Outpatient and Decentralised Settings

Burdened by aging demographic profiles and severe clinical workforce shortages, European public health systems are aggressively shifting patient care out of high-cost hospital environments.

Consequently, institutional capital is rotating rapidly toward technologies that facilitate "hospital-at-home" models, decentralised diagnostics, remote patient monitoring, and tech-enabled home care providers.

These services act as an immediate release valve for strained public health budgets, guaranteeing immediate demand and resilient payment profiles for operators.

Potential Surprises in the Next Six Months

The European HealthTech transaction landscape is highly dynamic, and several forward-looking catalysts are poised to disrupt standard investor expectations over the next six months.

AI-Enabled Diagnostic Advancements and Phase I Success Rates

The integration of machine learning and multi-omic data models in drug discovery is projected to nearly double Investigational New Drug (IND) application success rates, shifting Phase I probabilities of success from approximately 8% to 18%. This structural improvement dramatically shortens clinical validation timelines and reduces development costs.

Over the next six months, this accelerated validation cycle will trigger an unexpected wave of capital recycling and M&A activity, as large pharmaceutical firms aggressively target previously capital-deprived early-stage biotech assets to replenish pipelines ahead of looming patent cliffs.

Provider-Based Administrative Layoffs at Scale

As workflow automation and clinical AI documentation engines achieve widespread deployment in mid-2026, healthcare providers are projected to execute massive administrative layoffs. This workforce contraction will drive down operating costs for health systems but will simultaneously force software vendors to rapidly pivot their products.

Standalone administrative tools will face immediate obsolescence, while integrated enterprise-grade platforms that facilitate complete workflow automation will command unprecedented valuation premiums.

Regulatory Notice Delays and "Baby HSR" Bottlenecks

Transaction timelines face unexpected friction from the implementation of regional "Baby HSR" or "mini-HSR" notice and approval laws. Modeled on federal antitrust frameworks, these state and regional laws impose strict pre-merger review and approval requirements on healthcare transactions, even those falling below traditional monetary thresholds.

These regulations will delay transactions by 12 to 30 weeks, altering deal trajectories and forcing buyers to conduct extensive regulatory preparedness audits prior to launching formal bids.

Strategic Payer-Investor Collaborations

To combat reimbursement delays and persistent high medical costs, private equity sponsors are launching creative collaborative payor-investor models.

These partnerships mitigate current pressures on physician groups by reducing reimbursement lags, streamlining prior authorisation workflows, and facilitating the launch of lucrative ancillary services like decentralised diagnostics.

This collaboration provides a highly stable, diversified revenue stream that insulates portfolio assets from macroeconomic volatility.

The Race for Liquidity and Venture Capital Portfolio Overhang

The exit pipeline has effectively frozen for many European venture capital funds, creating severe portfolio congestion and intense pressure to return capital to Limited Partners (LPs).

Exit Avenue	Primary Structural Impediments	Resulting Market Behaviour
Initial Public Offering (IPO)	Domestically, the London Stock Exchange (LSE) carries a steep valuation discount compared to New York, making domestic listings structurally unattractive. FCA listing reforms have failed to restore foreign institutional demand, and compute constraints bake in structural discounts before pre-IPO due diligence begins.	High-growth companies are pushing listing timelines to a speculative 2027–2028 window, executing dual-track processes that fail to close, or dropping public offering plans entirely.
Strategic Trade M&A	Enterprise buyers are focused on rationalising vendor relationships rather than acquiring bolt-on assets. Cross-border transactions are restricted by regulatory scrutiny under frameworks like the UK National Security and Investment Act (NSIA), which imposes a 12-to-30 week clearance bottleneck on sensitive tech-adjacent deals.	Strategic acquirers are historically slower to get to closing, refuse to pay private equity premiums, and focus acquisitions on non-core, operationally painful capabilities.

The Secondary Market Standoff

GPs are left with limited options: accept deeply discounted secondary sales, seek formal fund life extensions, or initiate continuation vehicle processes.

The secondary market remains thin, with buyers bidding at deep discounts of 60p to 70p of carrying value.

For patient LPs navigating liquidity constraints, accepting such steep write-downs on fundamentally profitable portfolio companies is intolerable, meaning secondary transactions are also failing to clear.

Tax Reform as a Liquidity Driver

The UK Carried Interest Tax Reform implemented in April 2026 moves the taxation of carried interest from capital gains tax (CGT) rates directly to standard income tax rates. This fiscal change has dramatically altered the economics of holding assets through a prolonged exit drought. GPs are experiencing a new urgency to close whatever exits are currently achievable to crystallise returns before their carry economics are further impacted, forcing a compromise on valuation expectations to clear transactions.

This occurs alongside the Entrepreneurship Tax Relief Package enacted on April 6, 2026, which expands the Enterprise Management Incentives (EMI) scheme to scale-ups with up to £120 million in gross assets and 500 employees, and doubles Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) limits, though VCT income tax relief has been reduced to 20%.

The Incentives Gap in the "Messy Middle"

A structural dead zone has emerged containing the middle 70% of venture-backed portfolios. These companies are revenue-mature but lack the hyper-growth required to return the fund or interest large-cap investment bankers. While they are not broken businesses, they are stuck because VCs privately admit they would prefer to recycle capital rather than manage this middle tier.

Founders frequently destroy their remaining leverage by waiting until they have less than six months of runway to engage bankers, whereas a credible transaction requires six to nine months.

In 2026, runway is treated as a direct measure of negotiation leverage rather than just a financial metric.

Private Equity Roll Up Strategies and Platform Playbooks

With over $2.5 trillion in global dry powder and maturing 2019–2021 vintages, private equity sponsors are driving consolidation across the European healthcare landscape.

Rather than pursuing speculative standalone buyouts, PE sponsors are heavily deploying "buy-and-build" roll-up strategies. This playbook targets highly fragmented local markets, aggregates clinical or MedTech platforms, centralises back-office administrative functions, and infuses modern operational software.

PE funds exploit the valuation arbitrage between fragmented European SMEs (typically acquired at entry multiples of 8.4x to 10.4x EBITDA) and large strategic buyers (who acquire scaled, integrated pan-European platforms at premium multiples). These buy-and-build strategies demonstrate superior returns, yielding an average Internal Rate of Return (IRR) of 31.6% compared to 23.1% for standalone PE transactions.

Case Study: Pan-European MedTech Distribution (Sanviva)

The operational and regulatory dynamics of this trend are demonstrated by Axcel's consolidation of the medical technology distribution sector under the newly formed platform, Sanviva.

Platform Parameter	Details and Strategic Rationale
Sponsor & Funding	Funded through Axcel Elevate I, a lower mid-market fund that closed at its oversubscribed hard cap of €459 Million in November 2025.
Executive Leadership	Headquartered in Copenhagen, Denmark; led by newly appointed Group CEO Andreas von Scholten.
Consolidated Footprint	Simultaneous acquisition of four regional distributors: Apodan (Denmark), PartnerMed (Norway), AllweCare Medical (Netherlands), and XboXLab (Sweden), spanning six countries with 60 employees.
Logistics Integration	Regional inventory and warehousing are optimized using XboXLab's existing Gothenburg hub, featuring 1,250 square meters of warehouse space (including 310 square meters of cold storage).
Service Integration	Partnered with Nordic Service Group, deploying over 75 field engineers across the Nordics for equipment maintenance and calibration.

Sanviva operates as an integrated platform rather than a passive holding company, utilising several core operational strategies to drive commercial growth and efficiency. The platform eliminates costly country-by-country sales forces, providing global OEMs direct access to multiple regional healthcare markets through a single partnership. High-margin proprietary product lines are cross-sold across the network.

AllweCare's ostomy line (LaproCare) and scar therapy portfolio (ScarView) are expanding from Benelux into the Nordics by leveraging Apodan's clinical relationships and XboXLab's sales channels. Simultaneously, XboXLab's diagnostics are being integrated into AllweCare's distribution networks in Belgium and the Netherlands.

Public procurement accounts for roughly 70% of medical technology purchases in Europe. Sanviva operates a centralised tender management office with dedicated bid writers and legal experts to analyze historical data and submit optimised bids across decentralised national databases, such as Doffin (Norway), Hilma (Finland), and TendSign (Sweden).

To combat the overhead of MDR/IVDR, Sanviva centralises compliance, spreading regulatory costs over its massive revenue base. The platform utilizes the registered manufacturer status of AllweCare (EUDAMED Actor ID NL-MF-000004379), the quality certifications of Apodan (ISO 13485), and PartnerMed’s pharmaceutical wholesaling license to streamline cross-border regulatory compliance.

Acquisitions to Land and Expand: Partnerships and Vendor Sprawl Fatigue

Strategic acquirers are employing a highly disciplined "land and expand" methodology to mitigate execution risk and optimise capital efficiency.

The Corporate "Rent-to-Own" Model

Rather than executing outright acquisitions of early-stage software companies, corporate buyers increasingly default to commercial partnerships first. This model allows corporates to extensively test the product, validate its clinical efficacy, and understand integration and data security risks within real-world environments.

Acquirers only proceed to a formal acquisition once the build-versus-buy decision has resolved in favour of "buy," minimising integration failures and preserving balance sheet strength.

Corporate M&A is reserved for non-core, specialised, or operationally painful capabilities that accelerate their roadmap, while distressed acquisitions are executed strictly on the buyer's terms to absorb talent or technology.

Vendor Sprawl Fatigue and Point Solution Consolidation

Strained healthcare systems and enterprise IT architectures are experiencing severe "vendor sprawl fatigue". Procurement departments are actively consolidating vendors, favoring comprehensive, multi-module platforms over isolated point solutions. This buyer behaviour drives a wave of defensive strategic M&A, as standalone point solutions are forced to merge to form integrated clinical workflows or enterprise-scale operating systems to survive procurement rationalisation.

Strategic Channel Partnerships and Technical Interoperability

Relying solely on direct sales is highly inefficient, increasing the average sales cycle by 10%. Conversely, successful channel partnerships (marketing, co-sale, and contracting models) decrease the sales cycle by 25% and drop customer acquisition costs (CAC).

To prepare for technical audits during strategic exits, startups are fortifying their data plumbing, building REST-based interoperability utilising Fast Healthcare Interoperability Resources (FHIR) and HL7 connectivity protocols to link seamlessly with major EHR systems like Epic and Cerner. Founders must also navigate strict antitrust scrutiny of below-threshold deals, as evidenced by the French Competition Authority's November 2025 ruling and EUR 4,665,000 fine against Doctolib for abuse of dominance.

Valuation Predictions: Sub-Sector Multiples and European Unicorn Realities

The HealthTech valuation landscape reflects a fundamental transition from top-line revenue growth to a profit-weighted "Rule of 40" model, prioritising margin consistency and EBITDA visibility.

Sub-sector	EV / Revenue Multiple	EV / EBITDA Multiple	Strategic Rationale and Value Drivers
Premium AI & Data Platforms	6.0x – 12.0x+	15x – 20x+	Proprietary clinical datasets; validated AI models; deep EHR workflow integration.
AI-First Drug Discovery	8.0x – 15.0x	—	Milestone-driven potential; offsets looming pharma patent cliffs.
Value-Based Care (VBC)	5.5x – 7.0x	12x – 15x	Demonstrable, evidence-based ROI for payers; population health impact.
General HealthTech SaaS	4.0x – 6.0x	10x – 13x	Predictable unit economics; stable net revenue retention (NRR).
MedTech Hardware (MDR-ready)	3.5x – 5.5x	11x – 14x	Highly regulated; high barriers to entry; strategic compliance moats.
Consumer Health & Wellness	2.0x – 4.0x	8x – 11x	Lower switching barriers; highly sensitive to consumer discretionary spend.
Sub-scale / Unprofitable Assets	2.5x – 4.0x	—	Lacks proprietary clinical integration; distressed or unoptimized cash flows.

Leading European Healthcare Unicorns

The European venture ecosystem is showing selective recovery, with total global digital health funding reaching $28.8 Billion in 2025, and Europe leading with a 15% growth rate. Europe digital health funding hit $1.2 Bn in Q1 2026, signalling market maturity. Several scaled assets are positioning themselves for premium exits.

Unicorn Platform	Country of Origin	2026 Valuation	Focus and Strategic Positioning
Oura	Finland	$11.0 Billion	Transitioning from a consumer wearable device to a holistic, B2B preventative health platform integrated into enterprise corporate wellness plans.
Sword Health	Portugal	$4.0 Billion	Utilizing an "AI Care" model to deliver high-margin, automated alternatives to traditional physical therapy, significantly reducing payer delivery costs.
CMR Surgical	United Kingdom	$3.0+ Billion	Scaled as the sole viable European robotic surgery competitor to the dominant Da Vinci system.
Flo Health	United Kingdom	$1.0+ Billion	Dominating the FemTech menopause and B2B employee benefits sector, boosted by a $200 million financing round from General Atlantic.
Owkin	France	$1.0+ Billion	Utilising federated learning models to execute GDPR-compliant clinical trials and pharmaceutical research across fragmented hospital networks.

The Frontier AI Token Price War: Deflationary Dynamics and Workflow Economics

An aggressive, capital-fuelled deflationary cycle driven by intense competition among frontier model providers has drastically shifted the operating economics of the HealthTech industry.

Backed by monumental private financing rounds, including Anthropic's Series G funding at a $380 Billion post-money valuation and rapid algorithmic optimisation, API pricing for frontier reasoning models has collapsed.

Nominals vs. Tokeniser Realities

Anthropic implemented a historic 67% price reduction for its flagship Claude Opus tier, dropping input and output costs to $5.00 and $25.00 per million tokens (MTok). Concurrently, OpenAI positioned GPT-5.4 at $2.50/$15.00 per MTok and released capable, lightweight reasoning tiers such as o4-mini and GPT-4.1 Nano.

However, the release of Claude Opus 4.7 introduced a new tokeniser that consumes up to 35% more tokens for identical medical texts, creating a hidden volume premium. To maximise resource allocation, developers deploy cloud routing layers to automatically shift simpler queries to cheaper, faster models based on task type, compressing blended request costs by 40% to 60%.

Microeconomics of Clinical NLP and Scribing Workflows

The pricing collapse has dramatically altered the unit economics of ambient clinical documentation and complex chart ingestion.

Scenario	API Configuration	Cost per Encounter	Monthly Cost per Clinician (400 Encounters)	Strategic Implications
Scenario A: Simple Scribe (3k transcript, 2k standard template, 1k output)	2024 GPT-4 Turbo (Unoptimised)	$0.0800	$32.00	High marginal cost; unviable for massive health systems.
	2026 GPT-5.4 (No Caching)	$0.0275	$11.00	Moderate pricing; requires platform subsidisation.
	2026 GPT-5.4 (90% Caching)	$0.0230	$9.20	Optimized for baseline primary care workflows.
	2026 o4-mini (Budget Reasoning)	$0.0049	$1.98	Commoditises basic transcription; near-zero margin friction.
Scenario B: Complex Multi-Agent(15k template, 50k historical EHR, 3k live transcript, 2k output)	2024 GPT-4 Turbo (Flat Context)	$0.7400	$296.00	Cost-prohibitive for large-scale clinical deployment.
	2026 Claude Sonnet 4.6 (Cached)	$0.0585	$23.40	Economically viable for specialized clinical review.
	2026 o4-mini (Reasoning, Cached)	$0.0152	$6.06	Deep context understanding at highly disruptive price points.

The integration of prompt caching has completely restructured clinical RAG systems. Running an application with a 50,000-token system prompt used 500 times per day would cost roughly $75.00 daily without caching. With prompt caching enabled, the initial write costs $0.19, while the remaining 499 reads cost just $0.015 each, reducing the daily cost to roughly $7.69 and saving healthcare IT systems over $24,500 annually on a single prompt pipeline.

Demise of the Compliance Premium and Data Residency Geopolitics

Historically, software developers building clinical AI solutions paid flat compliance surcharges ranging from $500 to $2,000 per month or bought premium enterprise-only tiers to obtain a Business Associate Agreement (BAA). T

he token price war has democratised HIPAA compliance. Both OpenAI and Anthropic now integrate HIPAA-compliant infrastructure directly into their standard token-rate billing, turning compliance into a commoditised utility.

However, to comply with GDPR data residency laws, OpenAI has implemented a 10% premium surcharge for regional processing endpoints supporting local data residency on all models released after March 5, 2026. Additionally, "OpenAI for Healthcare" (launched in January 2026 and powered by clinical GPT-5.2 models) provides secure workspaces grounded in peer-reviewed medical papers, used by major health systems such as Cedars-Sinai and Memorial Sloan Kettering. To preserve patient trust, complete separation is maintained between "ChatGPT for Healthcare" (the enterprise provider tool) and "ChatGPT Health" (the consumer tool for medical records and wearables).

Strategic Polarisation: Winners and Losers from the Price War

The pricing collapse and concurrent capabilities expansion have triggered a major shakeout in the clinical AI landscape.

Scribe Wrappers and Standalone Point Solutions

Scribe wrappers and passive recording tools, such as Freed AI (Core at $79/month, Premier at $119/month) are highly vulnerable to native EHR tools. Since Epic Systems rolled out "Epic AI Charting" directly inside the EHR in February 2026 (capturing audio and drafting SOAP notes for free), clinicians are abandoning standalone tools to avoid manual copy-pasting.

Basic platforms facing clinician dissatisfaction are experiencing severe churn. Their accuracy falls sharply outside primary care, requiring weeks of manual template adjustments for specialties like orthopedics and psychiatry.

Furthermore, essential features (ICD-10 coding, referral letters) are locked behind premium tiers, and peak-hour processing delays can balloon up to five minutes, rendering them unviable for clinical environments.

Advanced EHR-Agnostic Platforms and Full-Stack Automation

High-tier platforms like Abridge and Nabla ($100–$250/month) remain resilient by acting as Epic Pal Partners with secure, real-time write-back capabilities directly into clinical charts. They leverage deep clinical relationships, offer high multi-speaker accuracy, and generate patient-facing after-visit summaries that standard wrappers cannot reproduce.

Advanced platforms are utilising cheap APIs to build full-stack clinical automation with 80% to 90%+ gross margins.

For example, DeepCura uses FHIR R4 APIs and the SMART authorisation framework to automate the entire clinician workflow—from medical history and diagnostics to prior authorisations and billing, generating concise, EHR-integrated clinical summaries that save hours of provider labour.

These winners are defined by superior technical capability. On clinical evaluation benchmarks, Claude 3.5 Sonnet leads anatomical recognition with a MURA accuracy of 57.0% and a ROCOv2 anatomical region accuracy of 85.0% (compared to 78.0% for GPT-4-Turbo). In SWE-Bench verified coding agent accuracy, GPT-5 leads with 88.6%, followed by Claude Sonnet 3.5 at 72.0%–80.0% and Claude Opus 4.1 at 78.0%.

Strategic Outlook and Recommendations

The 2026 European HealthTech M&A landscape requires a fundamental shift in strategy for founders, venture capital funds and private equity sponsors. The era of capital abundance has been replaced by an era of industrial discipline, where transaction activity concentrates around highly integrated, regulatory-fortified, and cash-flow-positive operating platforms.

For founders, relying solely on direct sales is no longer viable. Implementing co-sale and contracting partner channels reduces customer acquisition costs and accelerates enterprise health system penetration.

Founders must deploy their software on hyperscaler cloud marketplaces (such as AWS Marketplace for clinical data and security tools, or Microsoft Azure for administrative software) to bypass standard hospital procurement delays. During strategic partnerships, founders must limit legal exclusivity and Right of First Refusal (ROFR) clauses to short windows (30 to 90 days) tied directly to strict performance milestones, preserving long-term independence. Furthermore, under the Runway Leverage Decay Formula, starting an M&A process with less than 12 months of runway severely degrades negotiating leverage, meaning founders must align operations to achieve EBITDA-positive workflows or initiate structured transaction processes at least 18 months prior to capital depletion.

For venture capital General Partners, confronting the "Messy Middle" early is an operational necessity. Rather than continuing to support underperforming mid-tier portfolio assets with bridge financing, GPs must aggressively recycle capital from the middle 70% of their portfolios.

Initiating consolidation or early trade sales allows funds to return vital liquidity to LPs in a highly constrained market. Investment diligence must treat MDR/IVDR and EU AI Act compliance as a core valuation driver rather than an administrative checkbox, targeting TechBio assets that have secured structural compliance moats, as these are highly insulated from market copycats and command premium exit multiples.

For private equity sponsors, the focus must remain on accelerating buy-and-build strategies to exploit the valuation and regulatory arbitrage in fragmented European markets.

Aggregating regional SMEs and centralising their Quality Management Systems and tender management structures yields a highly defensible platform easily exited to global strategic buyers. PE platforms must utilize highly deflationary frontier AI models to centralise back-office operations and automate administrative, scheduling, and billing workflows. Transitioning portfolio companies from traditional product sales to recurring SaaS or maintenance subscription models will yield EBITDA improvements of up to 20%, driving outsized returns in a structurally transformed transaction landscape.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech